Results 21 to 30 of about 282,907 (338)

Hypertrophic Cardiomyopathy [PDF]

Cardiac Electrophysiology Clinics, 2010
Hypertrophic cardiomyopathy is a myocardial disease characterized by myocardial hypertrophy, disorganization of cardiac myocytes, and fibrosis. Twenty-five percent of patients have a dynamic left ventricular outflow tract gradient caused by the combined effects of rapid ventricular ejection, a narrowed outflow tract, and systolic anterior motion of the
Christopher, Critoph, Perry, Elliott
openaire   +4 more sources

Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters

BMC Cardiovascular Disorders, 2021
Background Light-chain (AL) amyloidosis is the most common type of systemic amyloidosis with poor prognosis. Currently, the predictors of cardiac involvement and prognostic staging systems are primarily based on conventional echocardiography and ...
Changhui Lei, Xiaoli Zhu, David H. Hsi, Jing Wang, Lei Zuo, Shengjun Ta, Qianli Yang, Lei Xu, Xueli Zhao, Yan Wang, Shiren Sun, Liwen Liu   +11 more
doaj   +1 more source

Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy

European Heart Journal, 2021
Aims Childhood-onset hypertrophic cardiomyopathy (HCM) is far less common than adult-onset disease, thus natural history is not well characterized. We aim to describe the characteristics and outcomes of childhood-onset HCM.
N. Marston, Larry Han, I. Olivotto, S. Day, E. Ashley, M. Michels, A. Pereira, J. Ingles, C. Semsarian, D. Jacoby, S. Colan, J. Rossano, S. Wittekind, J. Ware, S. Saberi, A. Helms, Carolyn Y. Ho   +16 more
semanticscholar   +1 more source

Hypertrophic Cardiomyopathy

Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2022
Hypertrophic cardiomyopathy (HCM) is a primary disease affecting the cardiac muscle and is characterized by heterogeneous genetic, morphological, functional and clinical features. The clinical presentation of HCM varies widely. Patients may be completely asymptomatic and identified incidentally.
Sarita Gore, Sunil Yogiraj Swami
openaire   +2 more sources

Hypertrophic Cardiomyopathy

Journal of Cardiovascular Development and Disease, 2023
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy resulting from a mutation in one of several cardiac sarcomeric proteins [...]
Asra K. Butt, Deya Alkhatib, Issa Pour-Ghaz, Sakiru Isa, Omar Al-Taweel, Ifeoma Ugonabo, Neeraja Yedlapati, John Lynn Jefferies   +7 more
openaire   +3 more sources

Left Atrial Reservoir Strain-Based Left Ventricular Diastolic Function Grading and Incident Heart Failure in Hypertrophic Cardiomyopathy

Circulation Cardiovascular Imaging, 2022
Background: The echocardiographic assessment of left ventricular (LV) diastolic dysfunction (LVDD) in patients with hypertrophic cardiomyopathy is complex and not well-established.
Hyun-Jung Lee, Hyung‐Kwan Kim, T. Rhee, You-jung Choi, In-Chang Hwang, Y. Yoon, Jun‐Bean Park, Seung‐Pyo Lee, Yong‐Jin Kim, G. Cho   +9 more
semanticscholar   +1 more source

Molecular Genetic Basis of Hypertrophic Cardiomyopathy.

Circulation Research, 2021
Hypertrophic cardiomyopathy (HCM) is a genetic disease of the myocardium characterized by a hypertrophic left ventricle with a preserved or increased ejection fraction.
A. Marian
semanticscholar   +1 more source

Low‐Dose Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy: A Real‐World Study in China [PDF]

Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Aims To evaluate the real‐world efficacy and safety of low‐dose (2.5 mg) mavacamten initiation in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Methods and Results This single‐center observational study (Zhongshan Hospital, China; Oct 2024–Apr 2025) enrolled 72 symptomatic oHCM patients (NYHA II/III, LVEF ≥ 55 ...
Wenlong Yang, Hui Shi, Rebecca Suchi Chang, Yin Zhang, A. Jixiang, Chunyu Wu, Juying Qian, Junbo Ge, Shuning Zhang, Baohui Xu   +9 more
wiley   +2 more sources

Toward Replacing Late Gadolinium Enhancement With Artificial Intelligence Virtual Native Enhancement for Gadolinium-Free Cardiovascular Magnetic Resonance Tissue Characterization in Hypertrophic Cardiomyopathy

Circulation, 2021
Supplemental Digital Content is available in the text. Background: Late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) imaging is the gold standard for noninvasive myocardial tissue characterization but requires intravenous contrast
Qiang Zhang, M. Burrage, E. Lukaschuk, M. Shanmuganathan, Iulia A. Popescu, C. Nikolaidou, Rebecca Mills, K. Werys, E. Hann, A. Barutcu, Suleyman D Polat, M. Salerno, M. Jerosch-Herold, R. Kwong, H. Watkins, C. Kramer, S. Neubauer, V. Ferreira, S. Piechnik   +18 more
semanticscholar   +1 more source

Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy

ESC Heart Failure, 2021
Aims Amiodarone reduces the incidence of atrial fibrillation (AF) following coronary artery bypass surgery; however, the benefit of perioperative amiodarone in patients undergoing septal myectomy (SM) for obstructive hypertrophic cardiomyopathy (oHCM ...
Evan F. Shalen, Stephen B. Heitner, Lana Al‐Rashdan, Reyhaneh Akhavein, Miriam R. Elman, Katherine L. Fischer, Lucy Q. Lin, Meghan Mannello, Babak Nazer, Howard K. Song, Ahmad Masri   +10 more
doaj   +1 more source